Favorable Outcomes of Preterm Infants with PNALD Treated with IV Fish Oil-Based Lipid Emulsion.

Objectives: To study the acute and long-term outcomes of preterm infants treated with an intravenous (IV) fish oil-based lipid emulsion (FishLE) for parenteral nutrition-associated liver disease (PNALD). Methods: Preterm infants 14 days to 24 months of age with anatomic short gut or severe intestinal dysmotility, serum direct bilirubin >=4 mg/dL, and requiring >60% calories from PN were eligible. Enrolled infants received 1 g/kg/day of FishLE until resolution of direct hyperbilirubinemia or return of enteral nutrition. Acute clinical effects and biochemical markers of liver function were monitored. Growth and developmental scores at 6 and 12 months postmenstrual age (PMA) were assessed and compared to controls matched by gestational age (GA). Results: Thirteen patients with mean GA of 28 +/- 4 weeks were treated and compared to 119 GA matched controls. Their mean direct bilirubin was 9.8 +/- 6.4 mg/dL at enrollment. All infants had resolution of cholestasis after study completion. There were no acute adverse events, deaths, or liver/intestinal transplants. Weight and head circumference were similar between FishLE treated patients and controls at 6 and12 month PMA. Cognitive and motor scores were decreased at 6 and 12 months PMA in FishLE treated infants. Logistic regression analysis showed that prolonged hospitalization was detrimental to cognitive and motor development, while treatment was not. Conclusions: The use of IV fish oil-based lipid emulsions in premature infants appears to be safe and reverses PNALD despite significant liver disease and intestinal failure. This therapy should be utilized in preterm infants with PNALD and followed long term to evaluate development. (C) 2016 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2bHZRgn
via IFTTT